Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw unusually large options trading activity on Monday. Investors purchased 47,875 call options on the stock. This is an increase of approximately 1,767% compared to the typical daily volume of 2,564 call options.
In other news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00. Following the transaction, the insider now owns 69,184 shares in the company, valued at approximately $940,210.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John F. Crowley sold 47,213 shares of Amicus Therapeutics stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the transaction, the chief executive officer now owns 375,214 shares in the company, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 250,390 shares of company stock worth $3,620,581. 3.40% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Great West Life Assurance Co. Can raised its holdings in Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 4,145 shares during the period. California Public Employees Retirement System raised its holdings in Amicus Therapeutics by 2.4% in the 3rd quarter. California Public Employees Retirement System now owns 181,000 shares of the biopharmaceutical company’s stock valued at $2,729,000 after buying an additional 4,200 shares during the period. Teachers Advisors LLC raised its holdings in Amicus Therapeutics by 0.9% in the 4th quarter. Teachers Advisors LLC now owns 663,936 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 5,858 shares during the period. Strs Ohio purchased a new stake in Amicus Therapeutics in the 3rd quarter valued at about $102,000. Finally, QS Investors LLC raised its holdings in Amicus Therapeutics by 4.9% in the 4th quarter. QS Investors LLC now owns 159,008 shares of the biopharmaceutical company’s stock valued at $2,288,000 after buying an additional 7,483 shares during the period.
Several research analysts have recently commented on FOLD shares. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Cowen reiterated a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Leerink Swann lifted their price target on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Finally, Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average price target of $19.06.
Shares of Amicus Therapeutics (NASDAQ FOLD) opened at $15.17 on Tuesday. The stock has a market cap of $2,804.11, a PE ratio of -8.29 and a beta of 1.46. Amicus Therapeutics has a fifty-two week low of $5.87 and a fifty-two week high of $17.40. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.
ILLEGAL ACTIVITY NOTICE: This report was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/02/20/traders-buy-large-volume-of-call-options-on-amicus-therapeutics-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.